Stabilise the balance sheet. Secure regulatory footing. Recover value in time-bound windows.
Pharmaceutical Turnaround & Recovery
Pharmaceutical Turnaround & Recovery: Control Under Clinical and Capital Pressure
Handle executes pharmaceutical turnaround and recovery mandates where clinical risk, regulatory exposure, and capital pressure converge. We structure and lead interventions that secure continuity of operations, protect approvals and licences, and recover value across brands, plants, and portfolios.
From distressed manufacturers and distributors to regional portfolio companies, we integrate law, capital, and strategy into a single execution model; restructuring obligations, ring-fencing critical assets, and stabilising core markets. UAE is our center of execution. Enforcement, governance, and recovery sit on one timeline, under one accountable partner.
Our Pharmaceutical Turnaround & Recovery Services: Built for Regulated Continuity
Handle leads high-stakes pharmaceutical recovery across the UAE and key export markets, engineered to stabilise operations while regulators, creditors, and counterparties are watching. We move from diagnostic to execution with firm control of legal, regulatory, and capital constraints.
Distressed Pharmaceutical Diagnostics & Control Plan
8–12 week assessment of cash, covenants, licences, and supply risk, converted into an executable recovery blueprint.
Regulatory, Licensing & Compliance Stabilisation
Engage regulators, secure interim compliance positions, protect critical approvals, and reset risk with structured remediation.
Balance Sheet Restructuring & Capital Recovery
Restructure debt, renegotiate covenants, and lock new capital or asset exit pathways without losing regulatory footing.
Strategic Divestments, M&A and Asset Carve-outs
Execute sales of brands, facilities, and non-core assets with clean regulatory, IP, and liability separation.
Why Work with a Pharmaceutical Turnaround & Recovery Expert
Pharmaceutical distress is never purely financial. It is regulatory, clinical, and reputational. Handle structures recovery where every decision is tested by health authorities, supply obligations, and cross-border compliance.
Our model integrates turnaround, legal enforcement, and capital strategy into one mandate. We control timelines with creditors, regulators, and investors so that manufacturing, distribution, and licensing remain intact while value is reconfigured.
- UAE-based execution with GCC and global regulatory awareness
- Integration of legal, financial, and operational levers into one recovery plan
- Regulator-facing strategies that preserve licences and market access
- Structured engagement with lenders, suppliers, and institutional investors
- Experience across generics, branded, biotech, and medical distribution platforms
- Outcome focus: continuity of critical operations, capital recovery, and enforceable restructurings
Better Ask Handle
Why Choose Us to Handle Your Pharmaceutical Turnaround & Recovery
Pharmaceutical turnaround demands control of law, capital, and regulation in the same room. We lead mandates that withstand scrutiny from boards, regulators, and counterparties.
Handle converts distressed pharmaceutical positions into structured recovery pathways, where obligations are sequenced, assets are protected, and decisions are enforceable across jurisdictions.
EnquireRegulator-Ready Strategy
Recovery plans designed to withstand inspection, audit, and approval processes in health and medicines authorities.
Integrated Law and Capital Execution
Legal restructuring, security enforcement, and capital raising executed within one controlled playbook.
Cross-Border Pharmaceutical Competence
Structuring that recognises multi-jurisdiction manufacturing, IP, licensing, and distribution architectures.
Time-Bound, Board-Level Reporting
Defined workstreams, reporting cadences, and milestones that keep boards and investors in full command.
Anchored in the Region’s Most Strategic Hubs
We work across the UAE’s leading financial centers, free zones, regulatory authorities, and courts; giving our clients certainty in both capital and law.
When your business turns legal, capital turns critical, and legacy turns strategic… #BetterAskHandle
What’s Included in Our Pharmaceutical Turnaround & Recovery Services
We lead pharmaceutical turnaround and recovery from first diagnostic to post-stabilisation handover, under one accountable mandate. Legal enforceability, regulatory continuity, and capital resilience anchor every decision.
Our teams operate alongside management and owners, converting distressed obligations, plants, and portfolios into structured options: restructure, refinance, divest, or consolidate.
- Rapid diagnostic of financial, contractual, and regulatory exposure
- Regulatory and licensing stabilisation plans with defined authority interfaces
- Liquidity and working capital stabilisation, including standstills and forbearance
- Debt and covenant restructuring, including security reconfiguration
- Distressed M&A, carve-outs, and asset-backed capital solutions
- Stakeholder negotiation: lenders, suppliers, regulators, and minority investors
- Implementation governance, project management, and post-turnaround oversight
“Before offering your business for M&A, you must raise it with discipline. Strengthen governance, restore financial clarity, and sharpen strategy. A parented business attracts investors with confidence, not discounts.”
Mohamed abu El-MakaremManaging Partner & Chairman
“Good litigation is disciplined project management. Clear filings, clean evidence, and a hearing plan that your board understands. That is how outcomes travel from courtroom to cash.”
Hamda Al FalasiPartner, Law & Arbitration
The Powerhouse of Law & Capital⚬
The Powerhouse of Law & Capital⚬
The Powerhouse of Law & Capital⚬
The Powerhouse of Law & Capital⚬
The Powerhouse of Law & Capital⚬
#BetterAskHandle⚬
#BetterAskHandle⚬
#BetterAskHandle⚬
#BetterAskHandle⚬
#BetterAskHandle⚬
Frequently Asked Pharmaceutical Turnaround & Recovery Questions
Handle leads pharmaceutical turnaround and recovery for sponsors, lenders, and operators in the UAE and beyond, structured for regulatory continuity, capital preservation, and enforceable restructurings.
When does a pharmaceutical business require a formal turnaround and recovery mandate?
A formal mandate becomes necessary when liquidity strain collides with regulatory or supply-chain risk. This includes breaches or near-breaches of covenants, delayed supplier payments, potential disruption to critical product lines, or warnings from regulators. At that point, informal measures no longer protect licences, contracts, or value. A structured turnaround removes ambiguity and puts law, capital, and operations on one controlled track.
How is pharmaceutical turnaround different from a standard corporate restructuring?
Pharmaceutical turnaround operates under clinical, regulatory, and quality regimes that do not tolerate missteps. Decisions on plant closures, product discontinuation, or workforce changes must be aligned with health authorities, pharmacovigilance obligations, and GMP requirements. Standard restructuring models ignore this regulatory layer and expose boards to enforcement and reputational damage. Our approach hardwires regulatory continuity into every financial and legal step.
How quickly can Handle stabilise a distressed pharmaceutical position?
The initial control phase is structured around an 8–12 week diagnostic and stabilisation window. Within that period, we secure visibility on cash, covenants, supplier exposure, and regulatory risks, and implement immediate protections where available. Longer-term restructuring or divestment timelines then proceed against this stabilised baseline. Speed is engineered into the mandate without sacrificing regulatory or legal enforceability.
What is your approach to dealing with health regulators during turnaround?
We treat regulators as central stakeholders, not secondary observers. Our teams structure engagement that is transparent on risks, realistic on timelines, and precise on remediation steps. We secure interim positions where possible, such as conditional approvals, phased compliance plans, or monitored operations. This preserves licensing and market access while recovery measures are executed.
How do you protect intellectual property and product registrations during recovery?
IP and registrations are treated as core assets that anchor value and future optionality. We map ownership, licensing, and encumbrances across jurisdictions, then ring-fence critical rights from unsecured operational risks where the law permits. In any sale, joint venture, or refinancing, IP and registrations are structured with clear allocation of liabilities and enforcement routes. This ensures that value transfer remains clean and enforceable.
Can Handle manage distressed M&A or divestment of plants and brands as part of turnaround?
Yes, divestment is built into many pharmaceutical recovery plans. We design and execute structured sales of brands, facilities, and non-core business units in parallel with balance sheet restructuring. Regulatory, labour, environmental, and product liability issues are addressed in transaction architecture, not left to post-closing dispute. The objective is simple: clean exit paths with enforceable allocations of risk.
How do you work with existing management and operational teams?
We operate alongside management, not around them. Governance is reset through a defined turnaround steering structure that clarifies decision rights, reporting, and escalation protocols. Operational leaders retain control of day-to-day execution while we drive legal, financial, and regulatory workstreams. This combination delivers both institutional discipline and on-the-ground realism.
What role do lenders and private capital play in pharmaceutical recovery mandates?
Lenders and private capital are core to any credible recovery path. We structure standstills, covenant resets, and new money arrangements that reflect regulatory timelines and operational realities, not generic financial models. Where capital must exit, we design instruments and processes that preserve asset value while enabling orderly repayment or transfer. The capital position is never left to informal negotiation.
How do you manage cross-border manufacturing and supply chain complexity?
We map the full supply chain, including cross-border manufacturing, packaging, and distribution nodes, then identify where legal and regulatory risks concentrate. Contracts, quality agreements, and logistics commitments are restructured to prioritise continuity of critical products and compliance with export and import controls. Where necessary, we reconfigure sourcing and distribution routes to align with the recovery plan. The objective is to keep product moving while the balance sheet is reset.
What does a typical Pharmaceutical Turnaround & Recovery engagement look like with Handle?
Engagement begins with a tightly scoped diagnostic that defines risk, options, and a time-bound action plan. We then deploy integrated teams across legal, capital, and operations to execute the agreed roadmap under a single statement of work. Reporting to boards and investors follows predefined cadences with clear metrics on stability, regulatory status, and value recovery. Once stabilised, we transition governance to a steady-state operating model or new ownership structure.
Our Insights.
Partner-led perspectives on law, capital, and strategy, shaped by live mandates and boardroom realities.
Insights
Dubai’s Secret Tech Power: 10 Mobile App Giants Transforming UAE Business (Advisors & Capital Firms Must Read)
Dubai’s Secret Tech Power: 10 Mobile App Giants Transforming UAE Business (Advisors & Capital Firms Must Read)
Dubai’s Secret Tech Power: 10 Mobile App Giants Transforming UAE Business (Advisors & Capital Firms Must Read)
UAE’s e& Drops Vodafone: $5.95B Cash-In Ends a Mega Deal, Fuels New M&A Moves
UAE’s e& Drops Vodafone: $5.95B Cash-In Ends a Mega Deal, Fuels New M&A Moves
UAE’s e& Drops Vodafone: $5.95B Cash-In Ends a Mega Deal, Fuels New M&A Moves
UAE Just Updated Air Taxi & Drone Rules: The Frequency Shift That Will Reshape M&A in Urban Mobility
UAE Just Updated Air Taxi & Drone Rules: The Frequency Shift That Will Reshape M&A in Urban Mobility
UAE Just Updated Air Taxi & Drone Rules: The Frequency Shift That Will Reshape M&A in Urban Mobility
Partner with Handle
Have a question or challenge? Reach out for tailored advice on law, capital, or strategy. Our experts respond promptly with clarity and solutions suited to your ambitions.
